Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF.
Furman WL, et al. Among authors: mcgregor lm.
J Clin Oncol. 2009 Sep 20;27(27):4599-604. doi: 10.1200/JCO.2008.19.6642. Epub 2009 Aug 17.
J Clin Oncol. 2009.
PMID: 19687340
Free PMC article.
Clinical Trial.